“十五五”医药出海新格局：国家平台托举“中国药，全球卖”

Core Viewpoint - The article highlights the significant growth and international expansion of China's pharmaceutical industry, emphasizing the government's support and the increasing number of Chinese pharmaceutical companies venturing abroad to enhance their competitiveness in the global market [3][4]. Industry Overview - China's pharmaceutical industry ranks second globally, with approximately 30% of innovative drugs under research worldwide. In 2025, 76 innovative drugs were approved for market, surpassing the 48 approved in 2024, marking a historical high [6]. - The total import and export value of China's pharmaceutical and medical device products reached $201.7 billion in 2025, reflecting a year-on-year growth of 1.18% [7]. Investment Trends - A survey indicated that 75% of responding pharmaceutical companies plan to maintain or expand their foreign investments, showcasing their determination and confidence in participating in international competition [8]. - The export of chemical preparations, such as penicillin and cephalosporins, saw growth rates of 26% and 6.7% respectively in 2025, with biological preparations in countries like Jordan, the Philippines, and Pakistan growing at an annual rate of 20% [8]. Government Support and Policies - The Chinese government has introduced several national-level initiatives to support the pharmaceutical industry's international expansion, including the establishment of regional platforms and a drug price registration system to enhance global pricing authority [10][11]. - New regulations effective from January 1, 2026, aim to facilitate exports by allowing GMP-compliant drugs to apply for export certificates regardless of their approval status in China, and extending the validity of export certificates from 2 to 3 years [12][13]. Infrastructure Development - Four major procurement platforms have been established to support pharmaceutical companies in their international endeavors, facilitating transactions and cross-border settlements [14]. - The China (Xinjiang) - Central Asia (Center) Pharmacy has already helped domestic pharmaceutical companies achieve export sales of 4.391 billion yuan [14].